Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Rabbit Polyclonal to Human IKBKB / IKK2 / IKK Beta
Rabbit Polyclonal (IgG) to Human IKBKB / IKK2 / IKK Beta
Human, Mouse, Rat
Western blot, Immunoprecipitation, ELISA
Human IKBKB / IKK2 / IKK Beta
Human, Mouse, Rat (tested or 100% immunogen sequence identity)
Protein A purified
Western blot (1:1000)
Specificity and Use
Synthetic peptide (KLH coupled) corresponding to residues at the C-terminus of human IKK beta.
Detects total IKK beta proteins. Does not cross-react with IKK alpha or IKK gamma. Species cross-reactivity: Mouse and rat.
Suitable for use in ELISA, Western Blot and Immunoprecipitation. Western Blot: 1:1000, incubate membrane with diluted antibody in 5% BSA, 1X TBS, 0.1% Tween-20 at 4?C with gentle shaking, overnight. Immunoprecipitation: 1:500.
10 mM HEPES, pH 7.5, 150 mM sodium chloride, 0.1 mg/ml BSA, 50% glycerol. No preservative added.
Short term: 4°C. Long term: Store at -20°C. Avoid freeze-thaw cycles.
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome.